Similar to neutrophils, circulating immune macrophage cells contribute to lung bleeding and damage caused by ANCA-associated vasculitis (AAV), a study showed. These circulating macrophages were found to have an abnormally activated DNA sensing system — typically used to detect foreign DNA and fight infections — that promotes inflammation. Deleting these macrophages…
Compared with standard glucocorticoid regimen, a reduced-dose regimen may lower the risk of death and serious infections, while not increasing the risk of kidney failure, in people with ANCA-associated vasculitis (AAV), according to a review study. No major differences between regimens were detected in terms of disease remission, relapse,…
Adding plasma exchange to standard treatment reduces the risk of kidney failure after one year, but does not improve survival in people with ANCA-associated vasculitis (AAV), a review study reports. Plasma exchange was also associated with an increased risk of serious infections — a previously unrecognized effect that may explain…
Tavneos (avacopan), in combination with rituximab, leads to high remission rates without a need for standard glucocorticoids in people with ANCA-associated vasculitis (AAV), according to a small, real-life study in France. These findings add to results from previous clinical trials, further supporting Tavneos as an effective first-line approach…
Poor kidney function and worse overall disease severity at diagnosis can predict kidney failure in adults with ANCA-associated vasculitis (AAV), according to a small single-center study in Turkey. In addition, AAV patients with either hypocomplementemia — low levels of complement proteins in the blood — or a five-factor score…
A two-dose rituximab regimen is as safe and works as well as the standard four doses in inducing remission in adults with severe granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), according to a review study. While these findings support the current use of either regimen in clinical practice…
Vasculitis UK has awarded a total of £200,000 (about $283,000) in four grants to research projects mostly focused on the development of new therapeutic approaches and biomarkers for ANCA-associated vasculitis (AAV) and other vasculitis. All grants, each about £50,000 (about $70,800), were given to researchers at academic institutions…
People with rare disorders have a worse healthcare experience than those affected by chronic diseases, according to the results of an international survey conducted by Eurordis-Rare Diseases Europe. Indeed, rare disease patients overall give their healthcare experience a medium-low rating, of 2.5 on a scale of 1 to 5,…
The first wave of COVID-19 in Europe severely disrupted access to care and raised stress and anxiety in people with rare diseases, negatively affecting their health and well-being, according to a survey conducted by Eurordis-Rare Diseases Europe. “People living with rare diseases in Europe have found themselves caught as collateral…
The European Medicines Agency (EMA) has agreed to review Vifor Pharma and ChemoCentryx’s application requesting the approval of avacopan to treat granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), the companies announced in a press release. GPA and MPA are two types of…
Get regular updates to your inbox.